Modification of feeding behaviour

Abstract

The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.

1 - 37 . (canceled) 
     
     
         38 . A method for weight control or treatment, in a subject, comprising administering an effective amount of an oxyntomodulin and one or more additional agents chosen from a Glucagon-like peptide-1 (GLP-1), a GLP-1 agonist, an amylin, a leptin, or an exendin-4. 
     
     
         39 . The method of  claim 38 , wherein the oxyntomodulin and the one or more additional agents has one or more of the following effects: decreases calorie intake or food intake; prevents or reduces weight; induces weight loss; controls appetite, satiety or hunger, reduces weight; reduces or prevents obesity; or increases energy expenditure. 
     
     
         40 . The method of  claim 38 , wherein the oxyntomodulin is a human oxyntomodulin. 
     
     
         41 . The method of  claim 38 , wherein the oxyntomodulin comprises the sequence of SEQ ID NO:9. 
     
     
         42 . The method of  claim 38 , wherein the weight control or treatment t is achieved by reducing levels of circulating ghrelin. 
     
     
         43 . The method of  claim 38 , wherein the oxyntomodulin is administered via a route peripheral to the brain. 
     
     
         44 . The method of  claim 43 , wherein the oxyntomodulin is administered by oral, rectal, intravenous, intramuscular, intraperitoneal, buccal, sublingual, nasal, subcutaneous, or transdermal administration, or by inhalation. 
     
     
         45 . The method of  claim 38 , wherein the one or more additional agents is administered via a route peripheral to the brain. 
     
     
         46 . The method of  claim 38 , wherein the one or more additional agents is administered by oral, rectal, intravenous, intramuscular, intraperitoneal, buccal, sublingual, nasal, subcutaneous, or transdermal administration, or by inhalation. 
     
     
         47 . The method of  claim 38 , wherein the one or more additional agents is administered at a dose of 0.1 nmoles or more per kg body weight of the subject. 
     
     
         48 . The method of  claim 38 , wherein the one or more additional agents is administered at a dose of up to 3.2 nmoles per kg body weight of the subject. 
     
     
         49 . The method of  claim 38 , wherein the oxyntomodulin is administered at a dose of 0.1 nmoles or more per kg body weight of the subject. 
     
     
         50 . The method of  claim 38 , wherein the oxyntomodulin is administered at a dose of up to 12 nmoles per kg body weight of the subject. 
     
     
         51 . The method of  claim 38 , wherein the oxyntomodulin is administered before a meal. 
     
     
         52 . The method of  claim 38 , wherein the oxyntomodulin is administered at a dose of 0.5 mg to 2 mg before a meal. 
     
     
         53 . The method of  claim 38 , wherein the oxyntomodulin and the one or more additional agents is administered simultaneously. 
     
     
         54 . The method of  claim 38 , wherein the oxyntomodulin and the one or more additional agents is administered sequentially in any order. 
     
     
         55 . The method of  claim 38 , which comprises administering GLP-1, or an agonist thereof. 
     
     
         56 . The method of  claim 38 , which comprises administering amylin. 
     
     
         57 . The method of  claim 38 , which comprises administering leptin. 
     
     
         58 . The method of  claim 38 , which comprises administering exendin-4. 
     
     
         59 . The method of  claim 38 , which further comprises administering PYY or an agonist thereof. 
     
     
         60 . The method of  claim 38 , wherein the subject is a human. 
     
     
         61 . The method of  claim 60 , wherein the subject is a overweight, obese or a diabetic.